UI 105
Alternative Names: UI-105Latest Information Update: 23 Mar 2024
At a glance
- Originator Korea United Pharm Inc
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 04 Mar 2024 Early research in Cancer in South Korea (Parenteral) before March 2024 (Korea United Pharm pipeline, March 2024)